Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path

Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path
Data from Lundbeck’s Phase 2 and 3 clinical trials of idalopirdine in Alzheimer’s patients, will be made available to researchers worldwide through the Critical Path for Alzheimer’s Disease (CPAD) consortium database, held by The Critical Path Institute (C-Path). The Phase 3 studies failed to meet their primary goals of improving cognitive abilities in those given this treatment. C-Path is an independent, nonprofit, public-private partnership with the U.S. Food and Drug Administration (FDA) that through consortia like CPAD, aims to bring together experts from regulatory authorities, industry, and patient advocacy organizations to speed and improve the process of therapy development for diseases that include Alzheimer’s. “We are delighted with this opportunity to share data wit
Subscribe or to access all post and page content.